MedTrace Logo

Epinephrine Nasal Drops for Epistaxis During Nasal Intubation

NCT06789549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-01-23

No results posted yet for this study

Summary

Epistaxis is the most common complication of nasotracheal intubation. Incidence of epistaxis during nasotracheal intubation ranges from 22% to 80%. Epistaxis during nasotracheal intubation can lead to several complications such as nasal discomfort, airway obstruction, and blood aspiration. The most commonly used and available topical vasoconstrictor in drop form is oxymetazoline. However, oxymetazoline may not always be available in some hospitals, so epinephrine can be used as an alternative nasal decongestant to reduce the incidence of epistaxis during nasotracheal intubation.

Conditions

  • Oral Surgery

Interventions

DRUG

epinephrine nasal drops

Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation

DRUG

oxymetazoline nasal drops

Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation

Sponsors & Collaborators

  • Universitas Padjadjaran

    lead OTHER

Principal Investigators

  • Iwan Fuadi, M.D., PhD · Faculty of Medicine Universitas Padjadjaran Bandung

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-03-20
Completion
2024-04-01

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06789549 on ClinicalTrials.gov